Zadaxin

Zadaxin®

Thymosin alpha 1, see there.
References in periodicals archive ?
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc.
SciClone Pharmaceuticals Inc (Foster City CA) posted a quarterly profit that beat market estimates, driven by strong sales of its hepatitis B treatment Zadaxin in China and lower research and development expenses.
The clinical trial will compare the triple combination therapy of Zadaxin, peginterferon alfa-2a and ribavirin to placebo, peginterferon alfa-2a and rebavirin to evaluate the benefit of adding Zadaxin to current therapy for hepatitis C patients who have failed to respond to previous treatment.
41% of the non-responder patients tested HCV RNA negative and 50% showed a virologic response after 24 weeks of a new triple therapy of ZADAXIN in combination with pegylated interferon alpha and ribavirin.
Both ZADAXIN and SCV-07 promote differentiation of T cells into the T helper 1 (Th1) subset.
SciClone Pharmaceuticals (San Mateo, CA; 650-358-3437) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for use of the company's lead drug, ZADAXIN plus lamivudine and famciclovir for the treatment of hepatitis B.
For the third quarter of 2015, both overall revenue as well as ZADAXIN revenue grew significantly: overall revenue grew 25%, and ZADAXIN revenue grew 22% compared to the same period last year.
SciClone has come to prominence recently as it is trying to establish that its hepatitis B treatment Zadaxin can improve the effectiveness of H1N1 flu vaccines now being developed by other companies.
ZADAXIN is the only non-interferon-based new drug that we know of currently in phase 3 HCV clinical trials in the U.
SciClone Pharmaceuticals (San Mateo, CA; 650-358-3437) announced that the European Patent Office has allowed the company a patent covering the use of ZADAXIN for the treatment of hepatitis C in non-responders.
ZADAXIN also is being evaluated in other late-stage clinical trials for the treatment of hepatitis B and certain cancers.